Melio Healhcare Ltd.

https://www.imubiosciences.com

IMUBiosciences was founded in 2021 by Dr Adam Laing (Chief Executive Officer), Dr Tom Hayday (Chief Scientific Officer) and Mario Cantero (Chief Operating Officer), based on ten years of research out of the laboratory of Professor Adrian Hayday at King’s College London. Applying AI-driven data analytics to immunology research crystalised further when COVID-19 emerged, and the team leveraged its technology to understand the human immune response to the virus. IMU Biosciences has further validated and fine-tuned its unique approach in partnership with leading pharmaceutical and biotech companies. The Company was initially seed funded by the European technology investor Kfund and other angel investors.? *

	Start	2019-03-14 established (s-off)
	Group	Melio Healh (Group) (IMU Biosciences)
	Predecessor	King’s College London

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	40 Basinghall Street c/o Mark Davies & Associates, City Tower
	City	EC2V 5DE London
		Address record changed: 2024-01-25

Basic data	Employees	n. a.

		* Document for »About Section«: IMU Bioscience (Melio Health UK Ltd.). (1/24/24). "Press Release: IMU Biosciences Secures £11.5 Million in Series A Funding to Revolutionise Immune Powered Precision Medicine". London.

		Record changed: 2024-01-25

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Melio Healh (Group) (IMU Biosciences)

[1] IMU Bioscience (Melio Health UK Ltd.). (1/24/24). "Press Release: IMU Biosciences Secures £11.5 Million in Series A Funding to Revolutionise Immune Powered Precision Medicine". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]